Preclinical studies have confirmed that MDM2 inhibitors activate wild-type p53 in fulvestrant-resistant breast cancer models, effectively inducing p21 expression and cell cycle arrest, thereby promoting apoptosis and inhibiting tumor growth (Lu et al., 2016). Here, TP53 is linked to breast cancer.